Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02210-0. Published online 9 February 2023.
In the version of this article originally published, there was a typographical error in the third row, fifth column, of the table in Figure 1, where the population number remaining at 30 months, now reading “7,” appeared originally as “17,” while the Data Availability section has now been updated to note that “The RNAseq dataset is available on dbGAP (https://dbgap.ncbi.nlm.nih.gov/) to researchers with an approved dbGAP profile as outlined on the website, using the accession number phs003199.v1.p1.” The changes are reflected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Soliman, H., Hogue, D., Han, H. et al. Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat Med 29, 3270 (2023). https://doi.org/10.1038/s41591-023-02309-4
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-023-02309-4
This article is cited by
-
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
Nature Cancer (2025)
-
Implication of an exosome-based gene signature for estimating clinical outcomes of triple-negative breast cancer and assisting in individualized therapy
Scientific Reports (2025)
-
Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer
npj Breast Cancer (2025)
-
Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interaction
Nature Communications (2025)
-
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)
Nature Cancer (2025)